Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany.

Moclobemide was compared with clomipramine for safety and efficacy in 2 groups of 15 patients each with endogenous depression. The drugs were given under double-blind conditions in increasing doses; 1 patient in the moclobemide group dropped out because of lack of efficacy. Mean final improvement on the Hamilton Rating Scale for Depression was 51% in the moclobemide group and 54% in the clomipramine group. Efficacy and tolerance were rated good or very good by 47% (moclobemide) and 53% (clomipramine) (NS). The results indicate that moclobemide is as effective as clomipramine in treating endogenous depression.